Peptidylglycine α-Amidating Monooxygenase and Adrenomedullin Measurement in Patients with Hepatic Cirrhosis
Biomarkers in Medicine · 2023
DOI: 10.2217/bmm-2023-0337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomarkers in Medicine, 2023. Verfasst von Jens P Goetze und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, 2100, Denmark. Hauptthemen laut MEDLINE: Adrenomedullin, Mixed Function Oxygenases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Background
Peptidylglycine α-amidating monooxygenase (PAM) is an enzyme involved in the maturation of regulatory peptides. Here we examined PAM activity and adrenomedullin (bio-ADM) concentrations in patients with hepatic cirrhosis and determined net changes across the liver, kidneys and leg. Materials & methods: A total of 48 patients with hepatic cirrhosis and 16 control subjects were included. All patients and controls underwent an invasive procedure with blood collected across organs.
Results
PAM activity was increased in cirrhotic patients but without a net change across the liver, leg or kidney. In contrast, bio-ADM concentrations were associated with severity of disease and found to be higher in venous blood from the liver.
Conclusion
Increased PAM activity in patients with hepatic cirrhosis may reflect other organs involved in cirrhotic disease. Severe liver disease is a life-threatening condition that affects people all over the world. To improve doctors' ability to diagnose the disease and to follow the disease as it progresses, there is a need for new tools. Biomarkers are often used as such tools for measuring the presence and severity of a disease. In this study, we examined two potential biomarkers in blood from patients with severe liver disease: peptidylglycine α-amidating monooxygenase (PAM) activity and bioactive adrenomedullin (bio-ADM). We examined whether these biomarkers are present in blood and in amounts associated with disease severity. We also tested if the diseased liver releases the biomarkers. We found that bio-ADM is increased in blood from patients with severe liver disease and that the liver itself releases bio-ADM to the bloodstream. For PAM activity, we also detected increased activity in blood associated with disease severity. In contrast, however, this biomarker was not shown to be released by the liver. Taken together, the two biomarkers may help to improve severe liver disease diagnosis and maybe allow for biochemical follow-up as the disease progresses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, 2100, Denmark.
- Department of Biomedical Sciences, Faculty of Health Sciences, Copenhagen University, Copenhagen, 2200, Denmark.
- Department of Clinical Physiology & Nuclear Medicine, Hvidovre Hospital, Hvidovre, 2650, Denmark.
- Gastroenterology Department, Colentina Clinical Hospital, Bucharest, 020125, Romania.
- Gastro Unit, Medical Division, Hvidovre Hospital, Hvidovre, 2650, Denmark.
- SphingoTec GmbH, Hennigsdorf, Germany.
ORCID-Profile: Jens P Goetze
Zitieren
APA
Goetze, J. P., Voiosu, A., Wiese, S., Schulte, J., Kaufmann, P., Bergmann, A., Bartels, E. D., & Møller, S. (2023). Peptidylglycine α-Amidating Monooxygenase and Adrenomedullin Measurement in Patients with Hepatic Cirrhosis. Biomarkers in Medicine. https://doi.org/10.2217/bmm-2023-0337
Vancouver
Goetze JP, Voiosu A, Wiese S, Schulte J, Kaufmann P, Bergmann A, et al. Peptidylglycine α-Amidating Monooxygenase and Adrenomedullin Measurement in Patients with Hepatic Cirrhosis. Biomarkers in Medicine. 2023. doi:10.2217/bmm-2023-0337
BibTeX
@article{Goetze2023,
author = {Goetze, Jens P and Voiosu, Andrei and Wiese, Signe and Schulte, Janin and Kaufmann, Paul and Bergmann, Andreas and Bartels, Emil D and Møller, Søren},
title = {Peptidylglycine α-Amidating Monooxygenase and Adrenomedullin Measurement in Patients with Hepatic Cirrhosis},
journal = {Biomarkers in Medicine},
year = {2023},
doi = {10.2217/bmm-2023-0337}
}
EUVIMED